After Covis' Makena pull, EU regulator flags safety and efficacy problems with similar preterm birth drugs
Fierce Pharma
MAY 17, 2024
A committee of the European Medicines Agency on Friday called for the withdrawal of preterm birth drugs containing 17-hydroxyprogesterone caproate (17-OHPC), citing safety and efficacy concerns. Following a controversy over Covis’ preterm birth drug Makena in the U.S.
Let's personalize your content